Glioblastoma — frontier options in Florida
30 open options
- TRIALPHASE2RECRUITING
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
ACT001 — 20 sites
- TRIALPHASE1 / PHASE2RECRUITING
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
TNG456 · abemaciclib — 15 sites
- TRIALPHASE1RECRUITING
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
ERAS-801 · ABBV-637 · ABBV-155 — 11 sites
- TRIALPHASE2RECRUITING
Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma
Bevacizumab · Biospecimen Collection · Computed Tomography — 3 sites
- EXPANDED ACCESSAVAILABLE
Expanded Access to Gallium Maltolate (GaM)
Gallium Maltolate — 3 sites
- TRIALPHASE2NOT_YET_RECRUITING
Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma
Archive Sample Retrieval · Biospecimen Collection · Chest Radiography — 3 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
Biopsy Procedure · Magnetic Resonance Imaging · Radiation Therapy — 127 sites
- TRIALPHASE1RECRUITING
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
Everolimus · Trametinib — 17 sites
- TRIALPHASE2RECRUITING
Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial
Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging · Fluciclovine F18 · Gadolinium-Chelate — 18 sites
- TRIALPHASE3RECRUITING
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
SonoCloud-9 (SC9) · Carboplatin · Lomustine — 55 sites
- TRIALNARECRUITING
Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma
Best Practice · Biospecimen Collection · Dietary Intervention — 3 sites
- TRIALPHASE2RECRUITING
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
DOC1021 · Tumor resection · Temodar (Temozolomide) — 18 sites
- TRIALNARECRUITING
Non-invasive Glioma Characterization Through Molecular Imaging
3T MRI Scanner — 1 site
- TRIALPHASE2RECRUITING
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Cancer Therapeutic Procedure · Cancer Therapeutic Procedure · Questionnaire Administration — 1 site
- TRIALPHASE2RECRUITING
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
silevertinib in combination with temozolomide · temozolomide (TMZ) — 25 sites
- TRIALNARECRUITING
Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma
Intensity Modulated Proton Therapy (IMPT) · Bevacizumab — 1 site
- TRIALPHASE2RECRUITING
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
PEP-CMV · Temozolomide · Tetanus Diphtheria Vaccine — 13 sites
- TRIALPHASE1RECRUITING
IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma
Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells — 1 site
- TRIALPHASE1RECRUITING
RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)
pp65 RNA loaded lipid particles, pp65 RNA-LPs (Drug Product 1 or DP1) · RNA loaded lipid particles, RNA-LPs (Drug Product 2 or DP2) — 1 site
- TRIALPHASE2NOT_YET_RECRUITING
FG001 Near-Infrared Fluorescence Imaging During Tumor Resection in Newly Diagnosed High-Grade Glioma
FG001 — 5 sites
- TRIALPHASE1RECRUITING
Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial
Radiation Therapy · Radiosurgery · Stereotactic Biopsy — 2 sites
- TRIALPHASE2RECRUITING
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Clinical Encounter · Home Health Encounter · Quality-of-Life Assessment — 2 sites
- EXPANDED ACCESSAVAILABLE
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
Ulixertinib (BVD-523) — 26 sites
- TRIALPHASE1RECRUITING
STARLITE for Unresectable High-Grade Gliomas
Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT) · Abacavir · Lamivudine — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Biospecimen Collection · Magnetic Resonance Imaging · Placebo Administration — 36 sites
- TRIALPHASE1RECRUITING
Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103 — 4 sites
- TRIALPHASE2RECRUITING
DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
DB107-RRV · DB107-FC — 1 site
- TRIALPHASE1RECRUITING
A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs) — 2 sites
- TRIALNARECRUITING
PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial
PRDR — 2 sites
- TRIALPHASE2RECRUITING
Study of Olutasidenib and Temozolomide in HGG
Olutasidenib + TMZ — 20 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.